Oncology

Evaluation of Prosigna's risk of relapse score as a predictor of response to multiagent neoadjuvant chemotherapy in HR+/HER2 breast cancer patients.

An update on recent progress in oncology managed care.

The Patient-Centered Oncology Care meeting provides a great opportunity for stakeholders from across healthcare to get together, and when that happens very good things can come from it, according to Peter Bach, MD, MAPP, director of Memorial Sloan Kettering Cancer Center's Center for Health Policy and Outcomes.

Earlier this year, the legislature laid the groundwork for Medicaid expansion to occur in 2016.

The American Society of Clinical Oncology has issued a statement asking for an improved evidence base for treating older adults with cancer.

A new study, published in JAMA Oncology has identified a widespread gap in counseling services for patients who undergo BRCA testing.

A study presented at the European Society of Cardiology meeting has found that cancer increases cardiac stress, which is further accentuated by chemotherapy.

Stand Up 2 Cancer, in collaboration with the American Association for Clinical Research, will be funding innovative research grants with a potential to further translational cancer research.

Adolescent and young adult cancer patients face multiple barriers to ensuring adequate care: from unsure providers to financial constraints. Improved care coordination and recognition of the needs of this population can lead to much improved outcomes.

Evidence-Based Oncology spoke with Rajen Mody, MBBS, from the University of Michigan Health System, about his experiences treating young cancer patients, the survivorship program offered by the University of Michigan, and next generation sequencing.

Changes in the healthcare marketplace are steadily pushing changes for physicians and specialty practices of all kinds. Blaming the 340B drug discount program is both misleading and unproductive.

The new test, developed by Dako, will provide information on the survival benefit of patients with non-squamous NSCLC treated with nivolumab.

Top managed care stories this week include how much waiting to see the doctor costs patients, Express Scripts announced it will cover both PCSK9 inhibitors, and HHS proposed simplifying rules for providers using electronic health record.

A new study published in JAMA Oncology has identified disparate survival outcomes across sites of care.

The PD-1 inhibitor antibody was approved by the FDA for use in patients who have progressed on platinum-based treatment.

With the final guidance expected in November, UK will follow Europe in the use of pembrolizumab in treating advanced melanoma patients refractory to previous treatment as well as those who have not been previously treated.

With new treatments helping patients with cancer to live longer, healthcare providers now have new issues of long-term survivorship to consider, said Joseph Alvarnas, MD, the editor-in-chief of Evidence-Based Oncology.

Through a multi-site, multidisciplinary approach, AYA@USC addresses the unique needs of young adult cancer patients, improving outcomes and bridging the care gap in this population.

Adolescent and young adults (AYA) constitute a distinct population amongst patients with cancer. Historically, AYA patients with ALL treated along pediatric-inspired protocols had better outcomes compared to those treated on standard "adult type" regimens.

My role as a patient was simple-accept the suffering I had to endure. But it becomes hard to find the line between when to suffer and when to question.

Steven Rosenberg, MD, chief of surgery at NCI's Center for Cancer Research, has been awarded the 2015 Samuel J. Heyman Service to America Medal, or Sammie for his contributions to the field of immune-based cancer treatments.

A retrospective follow-up in women who had received grafts of cryopreserved ovarian tissue discovered a 30% success rate in bearing a child.

Millions of Americans with serious illness, such as cancer, heart disease, kidney disease, and dementia, continue to have inadequate access to palliative care, according to the 2015 State-by-State Report Card from the Center to Advance Palliative Care.

Tumors caught early have a lower probability of advancing to the lymph nodes and improve patient outcomes, the BMJ study found.

The PD-L1 inhibitor was granted orphan drug status just last month.